



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 207/34, A61K 31/40	A1	(11) International Publication Number: WO 00/06541
		(43) International Publication Date: 10 February 2000 (10.02.00)

(21) International Application Number: PCT/EP99/05348

(22) International Filing Date: 21 July 1999 (21.07.99)

(30) Priority Data:
9816652.3 30 July 1998 (30.07.98) GB



(71) Applicant: PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).

(72) Inventors: COZZI, Paolo; Via Zanella, 48/5, I-20133 Milan (IT). CALDARELLI, Marina; Via Besenhanica, 9, I-20147 Milan (IT). BERIA, Italo; Via G. Matteotti, 39, I-45030 Villamarzana (IT). GERONI, Maria, Cristina; Via Correggio, 48, I-20149 Milan (IT). CAPOLONGO, Laura; Via P. Rembrandt, 11, I-20147 Milan (IT).

(81) Designated States: JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS



(57) Abstract

Compounds which are sulfurated distamycin derivatives of formula (I) wherein n is 2, 3 or 4; A is a bond, a C₁-C₄ alkylene or C₂-C₄ alkenylene group; R₁ and R₂, which are the same or different, are selected from hydrogen, C₁-C₄ alkyl optionally substituted by one or more fluorine atoms, and C₁-C₄ alkoxy; X is a halogen atom; B is selected from formulas (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and (k); wherein R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀, which are the same or different, are selected from hydrogen or C₁-C₄ alkyl; R₁₁ is hydrogen, C₁-C₄ alkyl or hydroxy, and m is 0, 1 or 2; or pharmaceutically acceptable salts thereof; are useful as antitumor agents.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS

The present invention relates to new alkylating antitumor agents analogous to Distamycin A, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents.

Distamycin A, whose formula is reported below



belongs to the family of the pyrroleamidine antibiotics and it is reported to interact reversibly and selectively with DNA-AT sequences, thus interfering with both replication and transcription. See, for a reference, Nature, 203, 1064 (1964); FEBS Letters, 7 (1970) 90; Prog. Nucleic Acids Res. Mol. Biol., 15, 285 (1975).

Several analogous to distamycin are known in the art.

DE-A-1795539 discloses distamycin derivatives in which the formyl group is replaced by a hydrogen atom or by the carboxylic acid residue of a C₁-C₄ aliphatic or cyclopentylpropionic acid.


EP-A-246,868 describes distamycin analogues in which the distamycin formyl group is substituted by aromatic, alicyclic or heterocyclic moieties bearing alkylating groups.

WO 97/28123 and WO 97/43258 describe distamycin analogues in which the amidino group is replaced with different nitrogen-containing ending groups and the distamycin formyl group is substituted by an aromatic or a cinnamoyl moiety, respectively.

It has now been found that a new class of distamycin derivatives as defined hereinunder, wherein the distamycin formyl group is substituted by a phenylcarbonyl, phenylalkylcarbonyl or phenylalkenylcarbonyl group bearing a haloethyl-thio group as an alkylating moiety, and the

amidino group is optionally replaced by various nitrogen-containing ending groups, shows valuable biological properties.

Therefore, the present invention provides compounds which
5 are sulfurated distamycin derivatives of formula:



wherein:


n is 2, 3 or 4;

A is a bond, a C₁-C₄ alkylene or C₂-C₄ alkenylene group;

10 R₁ and R₂, which are the same or different, are selected from hydrogen, C₁-C₄ alkyl optionally substituted by one or more fluorine atoms, and C₁-C₄ alkoxy;

X is a halogen atom;

B is selected from:



wherein R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀, which are the same or different, are selected from hydrogen or C₁-C₄ alkyl; R₁₁ is hydrogen, C₁-C₄ alkyl or hydroxy, and m is 0, 1 or 2;

20 or pharmaceutically acceptable salts thereof.

The present invention includes within its scope also all the possible isomers covered by the compounds of formula (I), both separately and in admixture, as well as the metabolites and the pharmaceutically acceptable bio-

25 pre-cursors (otherwise known as pro-drugs) of the compounds of formula (I).

In the present description, unless otherwise specified, both terms alkyl and alkoxy include straight or branched C₁-C₄ alkyl and alkoxy groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 5 tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

Preferred C₁-C₄ alkyl or alkoxy groups are methyl, ethyl, methoxy and ethoxy groups.

When substituted by one or more fluorine atoms, the C₁-C₄ 10 alkyl groups are preferably C₁-C₄ perfluoroalkyl groups, e.g. trifluoromethyl.

Both terms alkylene and alkenylene refer, respectively, to C₁-C₄ alkylene or C₂-C₄ alkenylene groups, as bivalent radicals of the corresponding C₁-C₄ saturated or C₂-C₄ 15 unsaturated hydrocarbons.

Preferred alkylene or alkenylene groups according to the present invention are methylene, ethylene or vinylene groups.

The term halogen atom includes fluorine, chlorine, bromine 20 and iodine, being chlorine and bromine preferred.

Within the compounds of formula (I) the haloethyl-thio group and the A group are in ortho, meta or para position with respect to each other; preferably, the haloethyl-thio and A groups are in meta or para position.

25 Pharmaceutically acceptable salts of the compounds of formula (I) are their salts with pharmaceutically acceptable either inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, succinic, malonic, citric, tartaric, 30 methanesulfonic and p-toluenesulfonic acid.

A preferred class of compounds of the present invention is that wherein, in formula (I):


n is 3;

A is a bond or vinylene;

35 R₁ and R₂ which are the same or different, are selected from hydrogen, methyl, methoxy or trifluoromethyl;

X is chloro or bromo;

B is selected from:



wherein R_3 , R_4 , R_5 , R_7 , R_8 , R_9 , R_{10} and R_{11} , which are the same or different, are selected from hydrogen or methyl; R_6 is hydrogen; and m is 0 or 1;

5 or the pharmaceutically acceptable salts thereof.

Examples of specific compounds according to the present invention, especially in the form of salts, preferably with hydrochloric acid, are the following:

- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 10 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 15 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 20 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 25 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N',N'-trimethylamidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 30 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;
 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
 chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;


- carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N-dimethylamine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
- 3-[1-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-

- carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;


- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 5 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile; and
- 10 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine.

A further object of the present invention is a process for preparing the compounds of formula (I), and the pharmaceutically acceptable salts thereof, which process comprises:

(a) when B is other than




reacting a compound of formula:




20

with a compound of formula:




wherein n, R₁, R₂, X and A are as defined above, and Y is hydroxy or a suitable leaving group;

25 so as to obtain a compound of formula:




and, then, optionally reacting a compound of formula (Ia) with:


- (i) $\text{H}_2\text{N}-(\text{CH}_2)_r-\text{NH}_2$, wherein r is 2 or 3, so as to obtain a compound of formula (I) having B equal to:




- (ii) $\text{H}_2\text{N}-\text{CH}_2-\text{CHO}$, so obtaining a compound of formula (I) having B equal to:




- (iii) $\text{H}_2\text{N}-\text{CN}$, so obtaining a compound of formula (I) having B equal to:



- (iv) $\text{H}_2\text{N}-\text{OR}_6$, so obtaining a compound of formula (I) having B equal to:




- (v) $\text{H}_2\text{N}-\text{NH}_2$, so obtaining a compound of formula (I) having B equal to:




- (vi) HNR_4R_5 , so obtaining a compound of formula (I) having B equal to:


-9-




and then optionally with H_2NR_1 , so obtaining a compound of formula (I) having B equal to:




- 5 (vii) succinic anhydride, so obtaining a compound of formula (I) having B equal to $-C\equiv N$;
- (viii) water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-CO-NR_9R_{10}$ wherein R_9 and R_{10} are both hydrogen atoms;
- 10 (ix) HNR_9R_{10} , so obtaining a compound of formula (I) having B equal to:



- and then with water in an alkaline medium, so obtaining a compound of formula (I) having B equal to
- 15 $-CO-NR_9R_{10}$, wherein R_9 and R_{10} are, each independently, hydrogen or C_1-C_4 alkyl; or
- (b) when B is other than




reacting a compound of formula:



20

with a compound of formula:



- wherein n, B, R₁, R₂, X, Y and A are as defined above;
 so obtaining the corresponding compound of formula (I);
 and, if desired, converting the compound of formula (I)
 5 into a pharmaceutically acceptable salt thereof.
- In formula (III), Y is hydroxy or a leaving group selected,
 for instance, from chloro, 2,4,5-trichlorophenoxy, 2,4-
 dinitro-phenoxy, succinimido-N-oxy, imidazolyl group, and
 the like.
- 10 The condensation reactions as set forth above under
 processes (a) and (b) is carried out according to known
 methods, for instance those described in the aforementioned
 EP-A-246,868.
- The reaction between a compound of formula (II) or (IV)
 15 with a compound of formula (III) is preferably carried out
 with a molar ratio (II):(III) or (IV):(III) of from 1:1 to
 1:2.
- Within the compounds of formula (III) wherein Y is hydroxy,
 the reaction is carried out in an organic solvent, such as,
 20 dimethylsulphoxide, hexamethylphosphotriamide,
 dimethylacetamide, dimethylformamide, ethanol, phenyl, or
 pyridine, in the presence of an organic or inorganic base
 such as triethylamine, diisopropyl ethylamine, or sodium or
 potassium carbonate or bicarbonate, and of a condensing
 25 agent such as, N-ethyl-N'-(3-dimethylamino-propyl)-
 carbodiimide, N,N'-dicyclohexyl-carbodiimide, or 1-hydroxy-
 benzotriazole hydrate.
- The reaction temperature may vary from about -10°C to about
 100°C, and the reaction time from about 1 to about 24
 30 hours.
- Within the compounds of formula (III) wherein Y is a
 leaving group as set forth above, the aforementioned
 condensation reaction may be carried out in an organic

solvent such as, for instance, dimethylformamide, dioxane, pyridine, tetrahydrofuran, or mixtures thereof with water, optionally in the presence of an organic or inorganic base, e.g. N,N'-diisopropylethylamine, triethylamine, sodium or potassium bicarbonate, at a temperature of from about 0°C to about 100°C, and for a time varying from about 2 hours to about 48 hours.

The reaction between a compound of formula (Ia) according to process (a) and one of the reactants as described above at points (i)-(vi) or (ix), can be carried out according to known methods, for instance those reported in US-4,766,142; WO 97/28123; Chem. Revs. 1961, 155; J. Med. Chem. 1984, 27, 849-857; Chem. Revs. 1970, 151; and "The Chemistry of Amidines and Imidates", edited by S. Patai, John Wiley & Sons, N.Y. (1975).

The reaction of a compound of formula (Ia) with succinic anhydride, as defined in point (vii) above, is preferably carried out with a molar ratio (Ia):succinic anhydride of from 1:1 to 1:3 in an organic solvent such as, for instance, dimethyl sulphoxide or dimethylformamide, and in the presence of an organic or inorganic base such as, e.g., triethylamine, diisopropylethylamine, sodium or potassium carbonate, and the like. The reaction temperature may vary from about 25°C to about 100°C, and the reaction time from about 1 hour to about 12 hours.

The reaction with water in an alkaline medium, as defined in points (viii) and (ix) above, may be carried out according to known methods usually employed for alkaline hydrolysis, for instance by treating the substrate with an excess of sodium or potassium hydroxide in water or in a water/organic solvent admixture, e.g. dioxane, tetrahydrofuran, or acetonitrile, at a temperature of from about 50°C to about 100°C, for a time varying from about 2 hours to about 48 hours.

The compounds of formula (II) are known or may be prepared according to known methods; see, for a reference, Arcamone et al. in Gazzetta Chim. Ital. 97, 1097 (1967).

Also the compounds of formula (III) are known or may be

prepared according to known methods, for instance by working as described in J. Org. Chem. 1993, 58, 4506-4508 or Helvetica Chimica Acta, Vol. 67, (1984), 1316-1327.

The compounds of formula (IV) are known compounds as well, for instance as reported in the aforementioned WO 97/28123. In view of what above reported, it is clear to the man skilled in the art that when preparing the compounds of formula (I) as set forth above, optional amino groups, i.e. R_1 and/or R_2 of the compounds of formula (IV) equal to hydrogen, need to be properly protected according to conventional techniques, so as to avoid unwanted side reactions.

Likewise, the conversion of the said protected amino groups into the free amines may be carried out according to known procedures. See, for a general reference, J. Org. Chem. 43, 2285, (1978); J. Org. Chem. 44, 811 (1979); J. Am. Chem. Soc. 78, 1359 (1956); Ber. 65, 1192 (1932); and J. Am. Chem. Soc. 80, 1154, (1958).

Salification of a compound of formula (I), as well as preparation of a free compound starting from a salt, may be carried out by known standard methods.

Well known procedures such as, e.g., fractional crystallisation or chromatography, may also be followed for separating a mixture of isomers of formula (I) into the single isomers.

The compounds of formula (I) may be purified by conventional techniques such as, e.g., silica gel or alumina column chromatography, and/or by recrystallisation from an organic solvent such as, e.g., a lower aliphatic alcohol, e.g. methyl, ethyl or isopropyl alcohol, or dimethylformamide.

PHARMACOLOGY

The compounds of formula (I) according to the present invention are useful as antineoplastic agents. Particularly, they show cytostatic properties towards tumor cells, so that they can be useful to inhibit growth of various tumors in mammals, including humans, such as, for

instance, carcinomas, e.g. mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumors. Other neoplasias in which the compounds of the present invention can find application are, for instance, sarcomas, e.g. soft tissue and bone sarcomas, and the hematological malignancies such as, e.g. leukemias.

The in vitro antitumor activity of the compounds of formula (I) was evaluated by cytotoxicity studies carried out on murine L1210 leukemia cells. Cells were derived from in vivo tumors and established in cell culture. The inhibition of cell growth was determined by counting surviving cells with a Coulter Counter after 48 hours treatment.

The in vitro activity was calculated on concentration-response curves and reported as IC_{50} (concentration inhibiting 50% of the cellular growth in respect to controls) were calculated on dose-response.

The compounds of the invention were tested also in vivo on L1210 murine leukemia and on murine reticulosarcoma M 5076, showing a very good antitumoral activity, with the following procedure.

L1210 murine leukemia was maintained in vivo by i.p. weekly transplantation in CD2F1 female mice, obtained from Charles River Italy. For experiments, 10^5 cells/mouse were injected i.v. in the same strain of mice. Animals were 8 to 10 weeks old at the beginning of the experiments. Compounds were administered i.v. at day +1 after tumor cells injections.

M5076 reticulosarcoma was maintained in vivo by i.m. serial transplantation. For experiments, 5×10^5 cells/mice were injected i.m. in the same strain of mice. Animals were 8 to 10 weeks old at the beginning of the experiments. Compounds were administered i.v. at day 3, 7 and 11 after tumor injection.

Survival time of mice and tumor growth were calculated and activity was expressed in term of T/C% and T.I.%.

$$T/C = \frac{\text{median survival time treated group}}{\text{median survival time untreated group}} \times 100$$

T.I.= % inhibition of tumor growth respect to control

Tox = number of mice which died for toxicity.

- 5 Tox determination was made when mice died before the control and/or tested significant body weight loss and/or spleen and/or liver size reduction were observed.

The compounds of the invention can be administered to
10 mammals, including humans, through the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, intramuscularly, subcutaneously, topically or orally. The dosage depends on age, weight and conditions of the patient and on the administration route. For example, a
15 suitable dosage for administration to adult humans may range from about 0.1 to about 150-200 mg pro dose 1-4 times a day.

Further object of the present invention are pharmaceutical compositions, which comprise a compound of formula (I) as
20 an active principle, in association with one or more pharmaceutically acceptable carrier and/or diluent.

The pharmaceutical compositions of the present invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form. For
25 instance, solutions for intravenous injection or infusion may contain as a carrier, for example, sterile water or preferably, they may be in the form of sterile aqueous isotonic saline solutions.

Suspensions or solutions for intramuscular injections may
30 contain, together with the active compound a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

35 In the forms for topical application, e.g. creams, lotions or pastes for use in dermatological treatment, the active ingredient may be mixed with conventional oleaginous or emulsifying excipients.

The solid oral forms, e.g. tablets and capsules, may contain, together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch and potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethyl cellulose, polyvinylpyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates, sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, for instance, lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulation. Said pharmaceutical preparations may be manufactured by known techniques, for example by means of mixing, granulating, tableting, sugar-coating or film-coating processes.

Further object of the present invention are the compounds of formula (I) for use in a method for treating the human or animal body by therapy.

Furthermore, the present invention provides a method for treating tumors in a patient in need of it, which comprises administering to said patient a composition of the invention.

A further object of the present invention is a combined method for treating cancer or for ameliorating the conditions of mammals, including humans, suffering from cancer, said method comprising administering a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an additional antitumor agent, close enough in time and in amounts sufficient to produce a therapeutically useful effect.

The present invention also provides products containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an additional antitumour agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

The term "antitumor agent" is meant to comprise both a single antitumor drug and "cocktails" i.e. a mixture of

such drugs, according to the clinical practice. Examples of antitumor agents that can be formulated with a compound of formula (I), or alternatively, can be administered in a combined method of treatment, include doxorubicin, daunomycin, epirubicin, idarubicin, etoposide, fluorouracil, melphalan, cyclophosphamide, 4-demethoxy daunorubicin, bleomycin, vinblastin, and mitomycin, or mixtures thereof.

The following examples are given to better illustrate the present invention but do not limit the scope of the invention itself.

Example 1

3-[1-methyl-4{1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine

Step I: The intermediate 4-(2-hydroxyethyl)thiobenzoic acid

To a solution of 400 mg of 4-thiobenzoic acid in 2.85 ml of NaOH 2N, 0.160 ml of 2-chloroethanol were added. The solution was refluxed for 1 hour, 2.85 ml of hydrochloric acid 2N were then added dropwise and the precipitated was filtered and dried giving 370 mg of a white solid.

FAB-MS: m/z 220, (60, [M+H]⁺)

PMR (CDCl₃) d:

7.61 (d, J= 15.7 Hz, 1H), 7.33 (m, 2H), 6.55 (m, 2H), 6.21 (d, J= 15.7 Hz, 1H), 4.22 (q, J=7.1 Hz, 2H), 3.9 (b.s., 1H), 3.19 (q, J=7.1 Hz, 2H), 1.25 (t, J=7.1 Hz, 3H), 1.28 (t, J=7.1 Hz, 3H).

By analogous procedures and by using the opportune starting materials the following intermediate compounds can be obtained:

3-methyl-4(2-hydroxyethyl)thiobenzoic acid;

4-(2-hydroxyethyl)thiocinnamic acid

FAB-MS: m/z 224

PMR (DMSO-d₆) d:

7.59 (m, 2H), 7.52 (d, J = 16.0 Hz; 1H), 7.31 (m, 2H), 6.46 (d, J= 16.0 Hz, 1H), 4.9 (bs, 1H), 3.57 (t, J=6.8 Hz, 2H),

3.08 (t, J=6.8 Hz, 2H).

Step II: The title compound

A solution of 240 mg of the intermediate, as prepared in step I, and 0.7 ml of thionyl chloride in 10 ml of toluene were refluxed for four hours, then the solvent was evaporated in vacuo. The crude residue was dissolved in 20 ml toluene and added portionwise to a solution of 500 mg of 3-[1-methyl-4-[1-methyl-4-[1-methyl-4-aminopyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidinium dihydrochloride (prepared as reported in J. Med. Chem 32, 774-778, 1989) and 160 mg of potassium bicarbonate in 10 ml of water.

The mixture was vigorously stirred at room temperature for one hour, the solvent was evaporated in vacuo and the crude residue purified by flash chromatography (methylene chloride/ methanol: 85/15) to yield 350 mg of the title compound as a white solid.

FAB-MS: m/z 652, (100, [M+H]⁺)

PMR (DMSO-d₆) δ:

10.34 (s, 1H), 9.98 (s, 1H), 9.92 (s, 1H), 8.9 (b.s., 2H), 8.6 (b.s., 2H), 8.21 (t, J=5.6 Hz, 1H), 7.91 (m, 2H), 7.47 (m, 2H), 7.32 (d, J=1.7 Hz, 1H), 7.24 (d, J=1.7 Hz, 1H), 7.18 (d, J=1.7 Hz, 1H), 7.10 (d, J=1.7 Hz, 1H), 7.06 (d, J=1.7 Hz, 1H), 6.95 (d, J=1.7 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H), 3.78 (t, J=7.3 Hz, 2H), 3.48 (m, 4H), 2.60 (t, J=6.5 Hz, 2H).

By analogous procedures and by using the opportune starting materials the following compounds can be obtained:

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidinium;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N',N'-trimethylamidinium;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-

- carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamide;
2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N-dimethylamine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;

- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio) cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
- 5 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio) cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 10 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio) cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;
- 15 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio) cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio) cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine.
- 20

Example 2

- 9) 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile
- 25

To a solution of 200 mg of 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride (prepared as reported in example 1) in 10 ml DMF were added 60 mg of potassium carbonate and 35 mg of succinic anhydride. The mixture was heated at 60°C for 2 hours. The solvent evaporated under vacuum and the crude residue purified by

35 flash chromatography (methylene chloride/methanol : 8/2) to yield 120 mg of the title compound as a white powder.

FAB-MS: m/z 635, (100, [M+H]⁺)

PMR (DMSO-d₆) δ:

10.30 (s, 1H), 9.96 (s, 1H), 9.91 (s, 1H), 8.31 (t, J=5.7 Hz, 1H), 7.90 (m, 2H), 7.48 (m, 2H), 7.32 (d, J=1.7 Hz, 1H), 7.24 (d, J=1.7 Hz, 1H), 7.20 (d, J=1.7 Hz, 1H), 7.08 (d, J=1.7 Hz, 1H), 7.05 (d, J=1.7 Hz, 1H), 6.93 (d, J=1.7 Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.78 (t, J=7.0 Hz, 2H), 3.44 (m, 4H), 2.72 (t, J=6.5 Hz, 2H).

By analogous procedure and by using the opportune starting materials the following compounds can be obtained:

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;

FAB-MS: m/z 680, (100, [M+H]⁺)

PMR (DMSO-d₆) d:

10.32 (s, 1H), 9.96 (s, 1H), 9.91 (s, 1H), 9.0 (b.s., 2H), 8.21 (t, J=5.6 Hz, 1H), 7.91 (m, 2H), 7.47 (m, 2H), 7.31 (d, J=1.7 Hz, 1H), 7.23 (d, J=1.7 Hz, 1H), 7.18 (d, J=1.7 Hz, 1H), 7.10 (d, J=1.7 Hz, 1H), 7.06 (d, J=1.7 Hz, 1H), 6.93 (d, J=1.7 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.44 (m, 4H), 3.00 (s, 3H), 2.77 (s, 3H), 2.71 (t, J=6.8 Hz, 2H).

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-

- chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N-dimethylamine;
- 3-[1-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine.

Example 3

- 14) 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine

Step I: The intermediate 4-(2-chloroethyl)thiocinnamic acid

- To a solution of 150 mg of 4-(2-hydroxyethyl)thiocinnamic acid (prepared as reported in example 1 step I) in 3 ml of pyridine, 0.105 ml of mesyl chloride were added and the solution was warmed for 2 hours at 80°C. The solution was cooled at room temperature and hydrochloric acid 37% was slowly added until pH=1. The precipitate obtained was filtered and washes with water then dried obtaining 100 mg of orange solid.

- 15 FAB-MS: m/z 242

PMR (DMSO-d₆) d:

12.3 (bs, 1H); 7.63 (m, 2H); 7.54 (d, J = 15.9 Hz, 1H); 7.34 (m, 2H); 6.48 (d, J = 15.9 Hz, 1H); 3.76 (t, J = 7.1 Hz, 2H); 3.40 (t, J = 7.1 Hz, 2H).

- 20 By analogous procedure and by using the opportune starting materials the following products can be obtained:

4-(2-chloroethyl)thiobenzoic acid;

FAB-MS: m/z 216

PMR (CDCl₃) d:

- 25 8.01 (m, 2H); 7.38 (m, 2H); 3.67 (d, J = 7.0 Hz, 2H); 3.35 (d, J = 7.0 Hz, 2H).

4-(2-bromoethyl)thiobenzoic acid;

3-methyl-4-(2-chloroethyl)thiobenzoic acid.

- 30 **Step II: The title compound**

- A solution of 95 mg of 4-(2-chloroethyl)thiocinnamic acid (prepared as described in step I), 80 mg of dicyclohexylcarbodiimide and 53 mg of 1-hydroxybenzotriazole hydrate in 5 ml of DMF was stirred at 80°C for four hours, cooled at room temperature and then added with 200 mg 3-[1-methyl-4-[1-methyl-4-[1-methyl-4-aminopyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine dihydrochloride (prepared as

reported in J.Med.Chem 32,774-778,1989) and 58 mg of potassium bicarbonate.

The mixture was stirred at room temperature for 2 hours, the solvent was evaporated in vacuum and the crude residue
5 purified by flash chromatography (methylene chloride/methanol: 8/2) to yield 130 mg of the title compound as a yellow solid.

FAB-MS: m/z 678, (100, [M+H]⁺)

PMR (DMSO-d₆) δ:

10 10.23 (s, 1H), 9.96 (s, 1H), 9.91 (s, 1H), 8.9 (b.s., 2H), 8.6 (b.s., 2H), 8.21 (t, J=5.6 Hz, 1H), 7.55 (m, 2H), 7.46 (d, J=75.8 Hz, 1H), 7.41 (m, 2H), 7.30 (d, J=1.7 Hz, 1H), 7.23 (d, J=1.7 Hz, 1H), 7.17 (d, J=1.7 Hz, 1H), 7.01 (d, J=1.7 Hz, 1H), 6.96 (d, J=1.7 Hz, 1H), 6.95 (d, J=1.7 Hz, 1H),
15 6.77 (d, J=15.8 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H), 3.76 (t, J=7.3 Hz, 2H), 3.49 (m, 2H), 3.40 (t, J=7.3 Hz, 2H), 2.60 (t, J=6.4 Hz, 2H).

By analogous procedure and using the opportune starting material the following product can be obtained:

20 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-

carboxamido]propionitrile;
2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-
chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-
carboxamido]pyrrole-2-carboxamido]pyrrole-2-
5 carboxamido]ethylguanidine.

Example 4

Tablets each weighing 0.250 g and containing 50 mg of the active substance can be manufactured as follows:

Composition for 10,000 tablets	
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide hydrochloride	500 g
Lactose	1,400 g
Corn starch	500 g
Talc powder	80 g
Magnesium stearate	20 g

10

3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide hydrochloride, lactose and half
15 of the corn starch were mixed; the mixture was then forced through a sieve of 0.5 mm mesh size.

Corn starch (10 g) was suspended in warm water (90 ml) and the resulting paste was used to granulate the powder. The granulate was dried, comminuted on a sieve of 1.4 mm mesh
20 size, then the remaining quantity of starch, talc and magnesium stearate was added, carefully mixed and processed into tablets.

Example 5

25 Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared as follows:

Composition for 500 capsules	
3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride	10 g
Lactose	80 g
Corn starch	5 g
Magnesium stearate	5 g

This formulation can be encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.


5 **Example 6**

Intramuscular Injection 25 mg/ml

An injectable pharmaceutical composition can be manufactured by dissolving 25 g of 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride in sterile propyleneglycol (1000 ml) and sealing ampoules of 1-5 ml.

CLAIMS

1. A compound which is a sulfurated distamycin derivative of formula:



wherein:


n is 2, 3 or 4;

A is a bond, a C_1 - C_4 alkylene or C_2 - C_4 alkenylene group;

R_1 and R_2 , which are the same or different, are selected from hydrogen, C_1 - C_4 alkyl optionally substituted by one or more fluorine atoms, and C_1 - C_4 alkoxy;

X is a halogen atom;

B is selected from:



wherein R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 and R_{10} , which are the same or different, are selected from hydrogen or C_1 - C_4 alkyl; R_{11} is hydrogen, C_1 - C_4 alkyl or hydroxy, and m is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R_1 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are, independently from each other, hydrogen, methyl or ethyl.


3. A compound according to claim 1 or 2 wherein n is 3;

A is a bond or vinylene;

R_1 and R_2 , which are the same or different, are selected from hydrogen, methyl, methoxy or trifluoromethyl;

X is chloro or bromo;

5 B is selected from:



wherein R_3 , R_4 , R_5 , R_7 , R_8 , R_9 , R_{10} and R_{11} , which are the same or different, are selected from hydrogen or methyl; R_6 is hydrogen; and m is 0 or 1; or a pharmaceutically acceptable
10 salt thereof.

4. A compound selected from the group consisting of:


- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
15 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
20 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
25 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N',N'-trimethylamidine;
30 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N',N'-trimethylamidine;

- carboxamido]propion-N-cyanamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N-dimethylamine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-


- bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
- 3-[1-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-bromoethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidoxime;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[3-methyl-4-(2-chloroethylthio)phenyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnaoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-methylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnaoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N,N'-dimethylamidine;
- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnaoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propion-N-cyanamidine;

- 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamido]propionamide;
- 5 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamide;
- 10 3-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionitrile;
- 15 2-[1-methyl-4[1-methyl-4[1-methyl-4[4-(2-chloroethylthio)cinnamoyl-1-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]ethylguanidine;
- and the pharmaceutically acceptable salts thereof.


5. A process for preparing a compound of formula (I) as defined in claim 1, which process comprises:
- (a) when B is other than



reacting a compound of formula:




- 25 with a compound of formula:




wherein n, R₁, R₂, X and A are as defined in claim 1, and Y

is hydroxy or a suitable leaving group;
so as to obtain a compound of formula:




and, then, optionally reacting a compound of formula (Ia)
5 with:


- (i) $\text{H}_2\text{N}-(\text{CH}_2)_r-\text{NH}_2$, where r is 2 or 3, so as to obtain a
compound of formula (I) having B equal to:




- (ii) $\text{H}_2\text{N}-\text{CH}_2-\text{CHO}$, so obtaining a compound of formula (I)
10 having B equal to:




- (iii) $\text{H}_2\text{N}-\text{CN}$, so obtaining a compound of formula (I) having B
equal to:



- (iv) $\text{H}_2\text{N}-\text{OR}_6$, so obtaining a compound of formula (I) having
15 B equal to:




- (v) $\text{H}_2\text{N}-\text{NH}_2$, so obtaining a compound of formula (I) having
B equal to:




- (vi) HNR_4R_5 , so obtaining a compound of formula (I) having B
20 equal to:


-32-



and then optionally with H_2NR_3 , so obtaining a compound of formula (I) having B equal to:




- 5 (vii) succinic anhydride, so obtaining a compound of formula (I) having B equal to $-C\equiv N$;
- (viii) water in an alkaline medium, so obtaining a compound of formula (I) having B equal to $-CO-NR_9R_{10}$ wherein R_9 and R_{10} are both hydrogen atoms;
- 10 (ix) HNR_9R_{10} , so obtaining a compound of formula (I) having B equal to:




- and then with water in an alkaline medium, so obtaining a compound of formula (I) having B equal to
- 15 $-CO-NR_9R_{10}$, wherein R_9 and R_{10} are as defined in claim 1; or:


(b) when B is other than



reacting a compound of formula:



20 with a compound of formula:



wherein n, B, R₁, R₂, X, Y and A are as defined above;
so obtaining the corresponding compound of formula (I) and,
if desired, converting the compound of formula (I) into a
5 pharmaceutically acceptable salt thereof.

6. A process according to claim 5 wherein, in the
compounds of formula (III), Y is hydroxy or a group
selected from chloro, 2,4,5-trichlorophenoxy, 2,4-dinitro-
10 phenoxy, succinimido-N-oxy and imidazolyl.

7. A pharmaceutical composition comprising one or more
pharmaceutically acceptable carriers and/or diluents and,
as the active principle, a compound as defined in claim 1.
15

8. A compound as defined in claim 1 for use in a
method of treatment of the human or animal body by therapy.

9. A compound as defined in claim 8 for use as an
20 antitumor agent.

10. Use of a compound as defined in claim 1 in the
manufacture of a medicament for use as an antitumor agent.

INTERNATIONAL SEARCH REPORT

International Application No

PC, EP 99/05348

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/34 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 43258 A (PHARMACIA & UPJOHN S.P.A.) 20 November 1997 (1997-11-20) cited in the application claims 1,2,4-10	1-3,5, 7-10
A	WO 97 28123 A (PHARMACIA & UPJOHN S.P.A.) 7 August 1997 (1997-08-07) cited in the application claims 1-3,5-11	1-3,5, 7-10
A	WO 97 03957 A (PHARMACIA & UPJOHN S.P.A.) 6 February 1997 (1997-02-06) claims 1,2,5-9	1-3,5, 7-10
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 November 1999

Date of mailing of the international search report

12/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PC./EP 99/05348

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	F. M. ARCAMONE ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 4, 1989, pages 774-8, XP000608784 cited in the application page 775, compound 4; page 776, table II; page 777, right-hand column, lines 35-52 ---	1-3,5,8,9
A	EP 0 246 868 A (FARMITALIA CARLO ERBA S.P.A.) 25 November 1987 (1987-11-25) cited in the application claims 1,2,5-9 ---	1-3,5,7-10
A	WO 94 20463 A (MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.) 15 September 1994 (1994-09-15) claims 1,2,9-12 ---	1,5,7-10
A	DD 297 638 A (FARMITALIA CARLO ERBA S.R.L.) 16 January 1992 (1992-01-16) claims 1,2,7,8 ---	1,7-10
A	US 5 395 849 A (M. D. WITTMAN ET AL.) 7 March 1995 (1995-03-07) claims 1,7-10,12; examples 1-4 -----	1,7-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 1 / EP 99/05348

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9743258	A	20-11-1997	AU 2701697 A EP 0912509 A NO 985307 A PL 329878 A	05-12-1997 06-05-1999 12-01-1999 12-04-1999
WO 9728123	A	07-08-1997	AU 1596097 A CA 2244139 A EP 0880499 A	22-08-1997 07-08-1997 02-12-1998
WO 9703957	A	06-02-1997	AU 6357996 A BR 9606528 A CA 2199635 A CN 1159183 A EP 0787126 A HU 9702393 A JP 10506410 T NO 971142 A PL 319352 A	18-02-1997 23-12-1997 06-02-1997 10-09-1997 06-08-1997 28-04-1998 23-06-1998 12-03-1997 04-08-1997
EP 246868	A	25-11-1987	AT 80617 T AU 597659 B AU 7316387 A BG 60531 B CA 1314551 A CS 9104137 A DE 3781716 A DK 254587 A FI 872173 A, B, GR 3006163 T HK 31993 A IE 60198 B IL 82553 A JP 1898111 C JP 6023193 B JP 62294653 A KR 9511408 B MX 9203122 A NZ 220361 A PT 84896 A, B SG 3793 G SU 1528316 A US 5017599 A US 5049579 A US 5310752 A ZA 8703593 A	15-10-1992 07-06-1990 26-11-1987 28-07-1995 16-03-1993 16-09-1992 22-10-1992 21-11-1987 21-11-1987 21-06-1993 08-04-1993 15-06-1994 10-06-1991 23-01-1995 30-03-1994 22-12-1987 04-10-1995 01-07-1992 26-04-1990 01-06-1987 12-03-1993 07-12-1989 21-05-1991 17-09-1991 10-05-1994 12-11-1987
WO 9420463	A	15-09-1994	IT 1271456 B AU 6206894 A CA 2157187 A EP 0690840 A JP 8508720 T	28-05-1997 26-09-1994 15-09-1994 10-01-1996 17-09-1996
DD 297638	A	16-01-1992	NONE	
US 5395849	A	07-03-1995	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)